Article thumbnail

Antiviral Res



Nipah virus (NiV) continues to cause outbreaks of fatal human encephalitis due to spillover from its bat reservoir. We determined that a single dose of replication-defective vesicular stomatitis virus (VSV)-based vaccine vectors expressing either the NiV fusion (F) or attachment (G) glycoproteins protected hamsters from over 1000 times LD50 NiV challenge. This highly effective single-dose protection coupled with an enhanced safety profile makes these candidates ideal for potential use in livestock and humans.CC999999/Intramural CDC HHS/United StatesT32 AI007610/AI/NIAID NIH HHS/United StatesU54 AI057158/AI/NIAID NIH HHS/United StatesU54-AI057158/AI/NIAID NIH HHS/United States2015-01-01T00:00:00Z24184127PMC38748897469vault:2352

Topics: Article, Henipavirus, Nipah, vaccine, VSV, single-dose, hamster, glycoproteins, Animals, Cricetinae, Disease Models, Animal, Drug Carriers, Henipavirus Infections, Mesocricetus, Nipah Virus, Survival Analysis, Vaccines, Synthetic, Vesiculovirus, Viral Structural Proteins, Viral Vaccines
OAI identifier: oai:cdc.stacks:cdc:45895
Provided by: CDC Stacks
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)

  • To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

    Suggested articles